JP2013526837A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526837A5
JP2013526837A5 JP2012539021A JP2012539021A JP2013526837A5 JP 2013526837 A5 JP2013526837 A5 JP 2013526837A5 JP 2012539021 A JP2012539021 A JP 2012539021A JP 2012539021 A JP2012539021 A JP 2012539021A JP 2013526837 A5 JP2013526837 A5 JP 2013526837A5
Authority
JP
Japan
Prior art keywords
recombinant listeria
listeria strain
her2
pharmaceutical composition
neu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539021A
Other languages
English (en)
Japanese (ja)
Other versions
JP5985397B2 (ja
JP2013526837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056534 external-priority patent/WO2011060260A2/en
Publication of JP2013526837A publication Critical patent/JP2013526837A/ja
Publication of JP2013526837A5 publication Critical patent/JP2013526837A5/ja
Application granted granted Critical
Publication of JP5985397B2 publication Critical patent/JP5985397B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539021A 2009-11-11 2010-11-12 組換えリステリア株およびそれを含む免疫原性組成物 Expired - Fee Related JP5985397B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26027709P 2009-11-11 2009-11-11
PCT/US2010/056534 WO2011060260A2 (en) 2009-11-11 2010-11-12 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152578A Division JP6329211B2 (ja) 2016-08-03 2016-08-03 脳腫瘍または乳腺腫瘍の発症を遅延させるための医薬の製造における組換えリステリア株の使用

Publications (3)

Publication Number Publication Date
JP2013526837A JP2013526837A (ja) 2013-06-27
JP2013526837A5 true JP2013526837A5 (enExample) 2013-12-26
JP5985397B2 JP5985397B2 (ja) 2016-09-06

Family

ID=43992418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539021A Expired - Fee Related JP5985397B2 (ja) 2009-11-11 2010-11-12 組換えリステリア株およびそれを含む免疫原性組成物

Country Status (4)

Country Link
US (1) US9084747B2 (enExample)
EP (1) EP2498808A4 (enExample)
JP (1) JP5985397B2 (enExample)
WO (1) WO2011060260A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2498808A4 (en) 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
LT2629791T (lt) * 2010-10-19 2017-02-27 Merial, Inc. Her2 dnr vakcina, kaip naminių gyvūnų vėžio papildomas gydymas
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
EP2825195A4 (en) * 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
MX2016010791A (es) 2014-02-18 2017-04-27 Advaxis Inc Inmunoterapia con multiples objetivos dirigida por biomarcadores.
CN103897067B (zh) * 2014-04-16 2016-04-13 中国医学科学院基础医学研究所 一种治疗肿瘤的重组多肽
MA39849A (fr) 2014-04-24 2017-03-01 Advaxis Inc Souches de listeria utilisées comme vaccin recombinant et procédé de production
SG11201609135VA (en) * 2014-05-02 2016-11-29 Univ Pennsylvania Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016011320A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CA2987239A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
MX2019005685A (es) 2016-11-30 2019-09-04 Advaxis Inc Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
KR102748132B1 (ko) 2017-09-19 2025-01-02 어드박시스, 인크. 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
KR20200130399A (ko) 2018-03-09 2020-11-18 어드박시스, 인크. 리스테리아 균주의 약독화 및 감염성을 평가하기 위한 조성물 및 방법
WO2019210034A1 (en) 2018-04-27 2019-10-31 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
BR112022026509A2 (pt) 2020-06-23 2023-03-07 Univ Colorado Regents Métodos para diagnosticar patógenos respiratórios e prever resultados relacionados à covid-19

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
KR20050084536A (ko) * 1997-04-17 2005-08-26 세키스이가가쿠 고교가부시키가이샤 도전성 미립자의 제조장치, 그 제조장치를 이용한 도전성미립자의 제조방법, 그 제조장치를 이용하여 이루어지는전자회로부품
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
EP1408048A1 (en) 2002-10-07 2004-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
CA2512812A1 (en) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
ES2684749T3 (es) 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008130551A2 (en) 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
EP2498808A4 (en) 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy

Similar Documents

Publication Publication Date Title
JP2013526837A5 (enExample)
Barbier et al. The clinical progress of mRNA vaccines and immunotherapies
Pandya et al. The future of cancer immunotherapy: DNA vaccines leading the way
US12319727B2 (en) Exosome-targeted DNA vaccine
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
ES2657168T3 (es) Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
JP2017507943A5 (enExample)
KR20190082850A (ko) 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
US20190032064A1 (en) Personalized Delivery Vector-Based Immunotherapy and Uses Thereof
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
KR20180026670A (ko) 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
JP2016503655A5 (enExample)
JP2017513502A5 (enExample)
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
CN106061995A (zh) Uspa2蛋白质构建体及其用途
JP2015511602A (ja) リステリアワクチン処理後のサプレッサー細胞機能抑制
KR20230004585A (ko) 개별화된 치료용 항암 백신
Lei et al. Cancer vaccines: platforms and current progress
Tadic et al. Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?
Daemi et al. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
Villegas-Mendez et al. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity
WO2014129412A1 (ja) 免疫原性ポリペプチド表層発現ビフィズス菌
CN1650014A (zh) 用于治疗肿瘤的作为编码细胞抗原的核苷酸序列的载体的微生物
Bae et al. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli
WO2018123507A1 (ja) 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療